SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists

Zoetis Inc. (New York Stock Exchange:ZTS)

US · Delayed Price · Currency is USD
73.31-0.24 (-0.33%)
 
Market Cap30.74B-50.9%
Revenue (ttm)9.52B+1.4%
Net Income2.62B+0.2%
EPS6.07+4.5%
Shares Out419.23M
PE Ratio12.06
Forward PE11.34
Dividend$2.09(2.85%)
Ex-Dividend DateJul 20, 2026
Volume5,441,829
Open73.50
Previous Close73.56
Day's Range73.09 - 74.08
52-Week Range71.00 - 152.00
Beta0.73
AnalystsHold
Price Target87.33(+19.12%)
Earnings DateNov 3, 2026
-0.34% (1D)
No price history available.

About ZTS

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Address
10 Sylvan Way, Parsippany, NJ, 07054, US
Market Cap
30.74 billion
Employees
14,500
Industrial Classification
Drug Manufacturers - Specialty & Generic
1 Day
-0.33%
5 Days
-2.35%
1 Month
-2.02%
6 Months
-39.15%
1 Year
-50.93%

$ZTS stock is featured in our Congress Trading, and Insider Trades datasets.

→ All Stock Lists

Congress Trading

Recent trades of ZTS by members of U.S. Congress

PoliticianTypeTraded
Gilbert CisnerosHouse / DSale$1.00K – $15.00KJul 17, 2026
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KJul 16, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KJun 15, 2026
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KApr 13, 2026
Gilbert Ray CisnerosHouse / DSale$1.00K – $15.00KMar 12, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KFeb 10, 2026
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KDec 18, 2025
Gilbert Ray CisnerosHouse / DPurchase$1.00K – $15.00KNov 17, 2025

Recently reported changes in ZTS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ZTS's directors and management

Net Shares Purchased by Insiders−1−102025Q32025Q42026Q12026Q22026Q3

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ZTS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ZTS Revenue by Segment or Geography

ZTS's latest filing doesn't break out revenue by segment.

Source: SEC EDGAR (10-Q/10-K)

U.S. Patents

New ZTS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ZTS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ZTS

ETFEst. Holding Size
VTIVanguard Morningstar Total Stock Market ETF$928.97M
VOOVanguard S&P 500 ETF$850.56M
VOVanguard Morningstar Mid-Cap ETF$631.13M
IVViShares Core S&P 500 ETF$418.23M
SPYState Street SPDR S&P 500 ETF$379.00M
VTVVanguard Morningstar Value ETF$277.99M

Estimated from each fund’s disclosed top holdings × AUM

ZTS Insider Score

Our composite score: insider buying, sector, volume, tone & dilution

No Insider Score for ZTS yet — no open-market insider buys or sells in the last 90 days.

Bull Case vs Bear Case

AI-generated from ZTS’s recent data — informational, not investment advice

Generating analysis…

Recent Insider Activity

Buys
0
Sells
0
Buy Value
$0
Distinct Buyers
0

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.